Samplimy
About the company
Samplimy develops patient-centric 3rd-generation microsampling technology that removes the legacy pain points of finger‑pricks, complex workflows, and cold‑chain logistics. Samplimy’s solutions enable painless self-sampling of both dermal interstitial fluid (dISF) and capillary whole‑blood (CWB) with one-step collection into a dry-stable format that can be sent by regular post to a lab.
This unlocks high‑resolution biodata for omics and AI‑driven models in pharma while making preventive care and population‑scale screening programs practically and economically feasible.
Founded as a spin‑off from world‑leading microsampling research at KTH in Stockholm, Samplimy combines proprietary device technology with ongoing academic development, with current focus on early research‑use customers and collaborations, application studies, and strategic partnerships as the foundation for a full commercial launch following the regulatory approvals.
Quick links:
Contact:
Name: Patrik Nilsson
Role: CEO / Co-founder
Email: pnilsson@samplimy.com
Phone: +46 707 82 33 44
LinkedIn
Capital need and valuation:
Capital Sought: €500k
Round Type: Pre-Seed
Pre-Money Valuation: €2.8M (to be discussed with lead investor)
Use of Funds
Product & technology development
- Finalization of both product MVPs.
- Develop seamless integration with analytical workflows, including reference SOPs and validated assay panels.
Go-to-market & customer acquisition
- Establish LOIs and commercial agreements with key-customers in beachhead markets.
- Secure pilot projects and potential early revenue selling sampling kits to early adopters in the research market.
Clinical & Science
- Evidence generation via studies with academia and life-science companies, within potential high-impact applications (e.g., skin cancer, diabetes). Verifying biomarker detection, analytical quality, and clinical relevance.
Team & key hires
- Engineer to accelerate product development and design-for-manufacturing.
- Bioanalysis/medical expert for internal lab work and research sales/relations.
- Part-time regulatory specialist to drive MDR preparations.
- Part-time sales/business developer to expand commercial reach and strategic partnerships.
Financial forecast
Projected Revenue:
2026 Pre-CE stage: <€50k (mainly pilots/studies)
2027 Pre-CE stage: <€200k (expansion from pilots and early research partners)
Revenue Model:
Pre-CE (RUO): Project-based direct sales of Lab-sampling kits (dISF), bundled with method set-up and support services.
Post-CE: Expansion to at-home sampling kits (dISF+CWB), with potential service/subscription models (e.g., through commercial partners with home-test providers or CROs).
Primary Value Drivers:
Samplimy dISF & CWB collectors:
- Virtually painless, minimally invasive self‑sampling that replaces tape‑stripping, biopsy, and frequent finger-pricks or venipuncture sampling, improving acceptance in sensitive populations.
- Enabling high‑frequency, longitudinal sampling at home or at the point of care, providing the dense biodata needed for omics and AI‑driven models.
- Access to unique local biomarker information from dermal interstitial fluid compared to systemic capillary whole blood, supporting deeper drug-tissue penetration insight and comparable concentrations between disease/treatment areas.
- Simple, one‑step collection process with precise sample volume, reducing pre‑analytical variability and the rate of collection‑stage lab errors associated with finger-prick DBS cards.
- Ambient‑compatible, low‑complexity logistics that lower costs and make large, geographically broad studies and screening programs feasible.
- Improved recruitment, compliance, and retention in clinical research and decentralized clinical trials, and more inclusive access to testing for children, elderly, needle‑phobic, and remote populations.
Traction and previous funding
Founder Investment: €X_
External Capital Raised: €1.5M (grants) + €36K (almi loan)
Key Traction Indicators: Pilots + LOIs
Strategic partnerships:
Close collaboration with SciLifeLab through ongoing research at KTH, with several grants awarded for ongoing studies with Samplimy’s devices. Most recently, for longitudinal monitoring in female health and diabetes.
Notable milestones achieved:
- 2 in-human studies, 1 published paper (ISF)
- 2 patent applications for interstitial fluid (ISF) and capillary whole blood (CWB) devices. 1 patent granted in US (ISF), EPO/US stage (ISF+CWB) – both expected to be granted.
- KTH-innovation + STING alumni (2025)
- First pilot project ongoing with Procter & Gamble’s global research unit (US), who preferred our technology over several competitors tested.
- 4 initiated studies with research partners, 3 via ongoing research at KTH. (fully financed)
Vision and impact
Example: Our long-term ambition is to (clear, credible vision)
Samplimy’s vision is a world where preventive care is the norm and more diseases are caught even before symptoms appear. The current wave of predictive omics and AI models already needs higher‑resolution, real‑world data to deliver on their promise.
Our ambition is to establish the gold standard for patient‑centric microsampling that enables frequent, large‑scale biodata collection for research, wellness, and population‑screening programs. In doing so, we help drive the shift towards preventive care and empower more people to make informed personal health decisions to improve global health.
The company contributes to sustainable value creation through (impact area), with alignment to relevant UN Sustainable Development Goals (SDGs) where applicable.
Samplimy contributes to sustainable value creation by improving access to essential health information and by enabling more efficient use of healthcare resources. Venipuncture‑based testing is costly, dependent on complex logistics and trained staff, and leaves a large share of the global population without timely diagnostics.
By offering simple, cost‑effective self‑sampling, Samplimy lowers the threshold for basic testing and follow‑up, supporting earlier care and reducing avoidable disease burden.
At the same time, our solutions give life‑science companies access to more diverse, longitudinal biodata, helping them develop therapies with improved efficacy across populations and geographies. In this way, Samplimy supports SDG 3 (Good health and well‑being) through earlier and smarter care, and SDG 10 (Reduced inequalities) by making diagnostics and research participation more accessible beyond well‑resourced healthcare systems.
Risk management
Key Risks:
Market adoption
Uptake of new microsampling technology in the research market may lag, as seen with first‑mover microsampling companies entering healthcare. The market is still in an early phase, and maturity will likely be sequential across segments and depend on alignment with stakeholders on the analytical side.
Mitigation
Our strategy is to start in the research market, where the analytical infrastructure is already well established. Our focus will be on segments with strong pain points, where we deliver clear operational, scientific, and economic benefits. Building success cases and data evidence to reduce friction for adoption in customer acquisition and new market entries.
Technology
Device performance might not consistently meet sensitivity, specificity, volume‑accuracy, or stability requirements across indications and demographics, which could limit trust and scale‑up.
Manufacturability issues could delay time‑to‑market.
Small sample volume, lab‑integration challenges, and assay‑compatibility constraints could limit access to certain applications and market verticals.
Mitigation
Initiate pilot projects to run iterative design cycles with early adopters and lab partners, using real‑world use-input and sample data to validate robustness across users and conditions, and feed results back into design and manufacturing.
Initiate studies together with researchers to validate device performace and analytical capacity. Build credibility and awareness through publications in these studies and engagement with KOL.
Regulatory
Delays in CE/FDA clearance due to capacity constraints at notified bodies and evolving requirements. Unexpected regulatory demands could postpone commercial launch, add cost, or force design changes.
Mitigation
We have already engaged with experts to define a clear regulatory roadmap. We will also engage early with notified bodies and regulators via pre‑submission meetings and scientific advice. We have initiated structured QA/RA documentation and risk management from the outset to prepare for the MDR-process.
Execution
With a small team and limited capital, we risk spreading resources too thin, as we need to execute on several tracks at once, which could slow progress on critical milestones.
Recruiting key competencies can also be challenging and align with the timeline.
Mitigation
Samplimy’s development and growth strategy is structured in phases with clear milestones and decision gates, ensuring we have the capacity and evidence needed before moving to the next step. In the current phase, we focus on validating product performance and key market needs before entering costly, path‑defining processes such as MDR. We will also expand our advisory group and board to bring in the right expertise and experience for each phase, ensuring the right focus towards our commercial roll-out.